KESTRA MEDICAL TECHNOLOGIES, LTD.KMTSEarnings & Financial Report
Kestra Medical Technologies, Ltd. is a medical device firm that develops, manufactures and commercializes innovative minimally invasive therapeutic solutions, mainly for interventional cardiology and structural heart disease treatment. It operates across North America, Europe and key Asia-Pacific markets, serving global healthcare providers and patients.
KMTS Q2 FY2026 Key Financial Metrics
Revenue
$22.6M
Gross Profit
$11.4M
Operating Profit
$-31.8M
Net Profit
$-32.8M
Gross Margin
50.6%
Operating Margin
-140.7%
Net Margin
-145.3%
YoY Growth
N/A
EPS
$-0.64
KESTRA MEDICAL TECHNOLOGIES, LTD. Q2 FY2026 Financial Summary
KESTRA MEDICAL TECHNOLOGIES, LTD. reported revenue of $22.6M for Q2 FY2026, with a net profit of $-32.8M (-145.3% margin). Cost of goods sold was $11.1M, operating expenses totaled $43.2M.
Key Financial Metrics
| Total Revenue | $22.6M |
|---|---|
| Net Profit | $-32.8M |
| Gross Margin | 50.6% |
| Operating Margin | -140.7% |
| Report Period | Q2 FY2026 |
KESTRA MEDICAL TECHNOLOGIES, LTD. Quarterly Revenue & Net Profit History
KESTRA MEDICAL TECHNOLOGIES, LTD. results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $22.6M | — | $-32.8M | -145.3% |
| Q1 FY2026 | $19.4M | — | $-25.8M | -133.3% |
Income Statement
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Revenue | $19.4M | $22.6M |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Assets | $266.3M | $246.7M |
| Liabilities | $82.1M | $82.6M |
| Equity | $184.2M | $164.1M |
Cash Flow
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Operating CF | $-26.3M | $-18.3M |